SCYNEXIS Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS or view top-rated stocks.

Wall Street analysts have given SCYNEXIS a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SCYNEXIS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

SCYNEXIS saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 650,500 shares, an increase of 97.2% from the January 14th total of 329,800 shares. Based on an average daily trading volume, of 518,400 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.2% of the company's shares are short sold.
View SCYNEXIS's Short Interest.

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for SCYNEXIS.

SCYNEXIS, Inc. (NASDAQ:SCYX) posted its earnings results on Friday, November, 6th. The company reported ($0.28) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.00) by $0.72.
View SCYNEXIS's earnings history.

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SCYX stock has increased by 5.9% and is now trading at $8.26.
View which stocks have been most impacted by COVID-19.

Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

7 equities research analysts have issued twelve-month target prices for SCYNEXIS's shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate SCYNEXIS's share price to reach $31.00 in the next year. This suggests a possible upside of 275.3% from the stock's current price.
View analysts' price targets for SCYNEXIS or view top-rated stocks among Wall Street analysts.

Some companies that are related to SCYNEXIS include CytomX Therapeutics (CTMX), Nature's Sunshine Products (NATR), Forte Biosciences (FBRX), Tonix Pharmaceuticals (TNXP), Paratek Pharmaceuticals (PRTK), VYNE Therapeutics (VYNE), CymaBay Therapeutics (CBAY), Immunic (IMUX), Immunome (IMNM), Trevena (TRVN), RedHill Biopharma (RDHL), Sesen Bio (SESN), Oncorus (ONCR), iBio (IBIO) and Graybug Vision (GRAY).
View all of SCYX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

SCYNEXIS's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (19.47%), Caxton Corp (13.48%), Avidity Partners Management LP (11.47%), Stonepine Capital Management LLC (6.26%), Renaissance Technologies LLC (1.18%) and Virtu Financial LLC (0.24%). Company insiders that own SCYNEXIS stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends for SCYNEXIS.

SCYX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for SCYNEXIS or view top insider-selling stocks.

SCYX stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Stonepine Capital Management LLC, Caxton Corp, Federated Hermes Inc., Renaissance Technologies LLC, Virtu Financial LLC, Diametric Capital LP, and Jane Street Group LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, and Scott Sukenick.
View insider buying and selling activity for SCYNEXIS or or view top insider-buying stocks.

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCYX stock can currently be purchased for approximately $8.26.

SCYNEXIS has a market capitalization of $90.36 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis.

SCYNEXIS employs 27 workers across the globe.

The official website for SCYNEXIS is www.scynexis.com.

SCYNEXIS is headquartered at 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302.

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]